Cangrelor: Review of the Drug and the CHAMPION Programme (Including PHOENIX)

New Therapies for Cardiovascular Disease (KW Mahaffey, Section Editor)
Part of the following topical collections:
  1. Topical Collection on New Therapies for Cardiovascular Disease

Abstract

Platelet inhibition is the main goal of ancillary pharmacologic therapy during percutaneous coronary interventions (PCI). Thienopyridines and ticagrelor are oral drugs developed for this purpose. Cangrelor is an intravenous, non-thienopyridine antagonist of the P2Y12 receptor with a rapid, potent, predictable, and quickly reversible effect. Cangrelor has been studied in a broad population intended to receive PCI in the CHAMPION program, where it was compared with different clopidogrel regimens. The first two trials, CHAMPION PCI and PLATFORM, failed their primary objective, likely for challenges in the adjudication of PCI-related myocardial infarction. In a third trial that implemented the universal definition of MI, CHAMPION PHOENIX, a reduction of thrombotic events, including stent thrombosis, was observed. In the BRIDGE trial cangrelor has been studied in patients who had to prematurely interrupt antiplatelet therapy for surgery. Cangrelor appears a promising agent in patients who require PCI or when a rapid reversal is needed.

Keywords

Cangrelor Percutaneous coronary interventions Platelet inhibition Acute coronary syndrome CHAMPION Programme 

Clinical Trial Acronyms

CHAMPION PCI

Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition PCI

CHAMPION PLATFORM

Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition PLATFORM

CHAMPION PHOENIX

Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition PHOENIX

BRIDGE

Maintenance of Platelet inihiBition With cangRelor After dIscontinuation of ThienopyriDines in Patients Undergoing surGEry

GUSTO

Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries

ACUITY

Acute Catheterization and Urgent Intervention Triage StrategY

TIMI

Thrombolysis in Myocardial Infarction

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Marcello Marino, Diego Rizzotti, and Sergio Leonardi declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44–e122.PubMedCrossRefGoogle Scholar
  2. 2.
    Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45(8):1157–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665–71.PubMedCrossRefGoogle Scholar
  4. 4.
    Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Mehta SR, Yusuf S. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21(24):2033–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Steinhubl SR, Berger PB, Mann 3rd JT, Fry ET, DeLago A, Wilmer C, et al. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA. 2002;288(19):2411–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:20.CrossRefGoogle Scholar
  11. 11.
    Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297–309.PubMedCrossRefGoogle Scholar
  12. 12.
    Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369(11):999–1010.PubMedCrossRefGoogle Scholar
  13. 13.
    Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50(19):1852–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.PubMedCrossRefGoogle Scholar
  15. 15.
    Fuller EE, Alemu R, Harper JF, Feldman M. Relation of nausea and vomiting in acute myocardial infarction to location of the infarct. Am J Cardiol. 2009;104(12):1638–40.PubMedCrossRefGoogle Scholar
  16. 16.
    Tricoci P, Peterson ED, Mulgund J, et al. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol. 2006;98:1172–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Lopes RD, Peterson ED, Chen AY, et al. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. JACC Cardiovasc Interv. 2010;3:669–77.PubMedCrossRefGoogle Scholar
  18. 18.
    Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5(6):797–804.PubMedCrossRefGoogle Scholar
  19. 19.
    Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61(15):1601–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218–30.PubMedCrossRefGoogle Scholar
  21. 21.
    Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007;297(6):591–602.PubMedCrossRefGoogle Scholar
  22. 22.
    Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360(21):2176–90.PubMedCrossRefGoogle Scholar
  23. 23.
    De Luca G. Glycoprotein IIb-IIIa inhibitors. Cardiovasc Ther. 2012;30(5):e242–54.PubMedCrossRefGoogle Scholar
  24. 24.
    Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost. 2001;85(3):401–7.PubMedGoogle Scholar
  25. 25.
    Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50(1):27–35.PubMedCrossRefGoogle Scholar
  26. 26.
    Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res. 2007;100:1261–75.PubMedCrossRefGoogle Scholar
  27. 27.
    Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008;121:527–34.PubMedCrossRefGoogle Scholar
  28. 28.
    Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost. 2008;6:1153–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneouscoronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006;151(3):689.e1–689.e10.CrossRefGoogle Scholar
  30. 30.
    Greenbaum AB, Ohman EM, Gibson CM, Borzak S, Stebbins AL, Lu M, et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J. 2007;154(4):702–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 2002;13(7):407–13.PubMedCrossRefGoogle Scholar
  32. 32.
    Jacobsson F, Swahn E, Wallentin L, Ellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectorisand non-Q-wave myocardial infarction. Clin Ther. 2002;24(5):752–65.PubMedCrossRefGoogle Scholar
  33. 33.
    Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361:2330–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361:2318–29.PubMedCrossRefGoogle Scholar
  35. 35.
    White HD, Chew DP, Dauerman HL, Mahaffey KW, Gibson CM, Stone GW, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012;163:182–90.PubMedCrossRefGoogle Scholar
  36. 36.
    Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525–38.PubMedCrossRefGoogle Scholar
  37. 37.
    Leonardi S, Truffa AA, Neely ML, Tricoci P, White HD, Gibson CM, et al. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart. 2013;99(17):1282–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Leonardi S, Mahaffey KW, White HD, Gibson CM, Stone GW, Steg GW, et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012;163:768–76.PubMedCrossRefGoogle Scholar
  39. 39.
    Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551–67.PubMedCrossRefGoogle Scholar
  40. 40.•
    Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303–13. The first phase III study in which cangrelor showed its efficacy and safety.PubMedCrossRefGoogle Scholar
  41. 41.
    Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382(9909):1981–92.PubMedCrossRefGoogle Scholar
  42. 42.
    Généreux P, Stone GW, Harrington RA, Gibson CM, Steg PG, Brener SJ, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX trial (Clinical trial comparing cangrelor to clopidogrel standard of care therapy in subjects who require percutaneous coronary intervention). J Am Coll Cardiol. 2014;63(7):619–29.PubMedCrossRefGoogle Scholar
  43. 43.
    Sardar P, Nairooz R, Chatterjee S, Mushiyev S, Pekler G, Visco F. Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials. J Thromb Thrombolysis. 2013 Sep 22. [Epub ahead of print].Google Scholar
  44. 44.
    Pandit A, Aryal MR, Pandit AA, Jalota L, Hakim FA, Mookadam F, Lee HR, Tleyjeh IM. Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis. EuroIntervention. 2013 Sep 30.Google Scholar
  45. 45.
    Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307(3):265–74.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Marcello Marino
    • 1
  • Diego Rizzotti
    • 2
  • Sergio Leonardi
    • 2
  1. 1.University of PaviaPaviaItaly
  2. 2.Fondazione IRCCS Policlinico San MatteoPaviaItaly

Personalised recommendations